Abstract | OBJECTIVE: DESIGN: SETTING: Multi-institutional. PATIENTS AND METHODS: Twenty consecutive patients received 100 to 400 mg of fluconazole per day for a median of 30 weeks. All had either failed to respond to treatment with more than 2 g of amphotericin B or had serious amphotericin B-related toxicities. RESULTS: Fourteen of 16 evaluable patients (88%) responded. Responses were observed in seven of nine patients in whom adequate doses of amphotericin B had failed and in all seven patients who had amphotericin B-related toxicities. In 12 patients, cytotoxic chemotherapy was continued without flare of the infection. Fluconazole was well tolerated with rare side effects. Aspergillus superinfection developed in three patients and contributed to the death of two of them. CONCLUSION:
|
Authors | E Anaissie, G P Bodey, H Kantarjian, C David, K Barnett, E Bow, R Defelice, N Downs, T File, G Karam |
Journal | The American journal of medicine
(Am J Med)
Vol. 91
Issue 2
Pg. 142-50
(Aug 1991)
ISSN: 0002-9343 [Print] United States |
PMID | 1867240
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Amphotericin B
- Fluconazole
|
Topics |
- Adult
- Aged
- Amphotericin B
(adverse effects, therapeutic use)
- Candidiasis
(drug therapy)
- Child, Preschool
- Chronic Disease
- Female
- Fluconazole
(therapeutic use)
- Humans
- Leukemia, Myeloid, Acute
(complications)
- Liver Diseases
(drug therapy, microbiology)
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(complications)
- Remission Induction
- Retrospective Studies
- Splenic Diseases
(drug therapy, microbiology)
- Superinfection
|